[HTML][HTML] Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity
…, S Das, J Ramirez, B Poonkuzhali… - Journal of clinical …, 2008 - ncbi.nlm.nih.gov
… We have recently identified four functional polymorphisms in the 5′-regulatory region of
ABCG2 (Poonkuzhali et al, manuscript submitted for publication). The −15994G>A (rs7699188) …
ABCG2 (Poonkuzhali et al, manuscript submitted for publication). The −15994G>A (rs7699188) …
Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation
… Age, serum bilirubin level, ferritin level, aspartate aminotransferase (AST) level, alanine
aminotransferase (ALT) level, hepatitis B or C virus infection, and Lucarelli et al's 21 …
aminotransferase (ALT) level, hepatitis B or C virus infection, and Lucarelli et al's 21 …
Transporter-mediated protection against thiopurine-induced hematopoietic toxicity
…, H Nakauchi, C Marzolini, RB Kim, B Poonkuzhali… - Cancer research, 2008 - AACR
Thiopurines are effective immunosuppressants and anticancer agents, but intracellular
accumulation of their active metabolites (6-thioguanine nucleotides, 6-TGN) causes dose-limiting …
accumulation of their active metabolites (6-thioguanine nucleotides, 6-TGN) causes dose-limiting …
Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia
AP Rajkumar, B Poonkuzhali, A Kuruvilla… - International clinical …, 2013 - journals.lww.com
Fixed oral doses of clozapine produce up to 45-fold interindividual variability among its
serum levels in patients with treatment-resistant schizophrenia. Although the relationship …
serum levels in patients with treatment-resistant schizophrenia. Although the relationship …
Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience
A total of 11 children (five males and six females) with hypergranular type of acute promyelocytic
leukemia (APML) were treated with intravenous arsenic trioxide (As 2 O 3) between …
leukemia (APML) were treated with intravenous arsenic trioxide (As 2 O 3) between …
Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms
… B, snapshot from the ECR browser with alignment of human BCRP with mouse and rat. C,
results from the rVISTA browser with local alignment of mouse and human BCRP. D, Cister …
results from the rVISTA browser with local alignment of mouse and human BCRP. D, Cister …
A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression
…, RG Tirona, G Gervasini, B Poonkuzhali… - Molecular …, 2007 - academic.oup.com
The farnesoid X receptor (FXR or NR1H4) is an important bile-acid-activated, transcriptional
regulator of genes involved in bile acid, lipid, and glucose homeostasis. Accordingly, …
regulator of genes involved in bile acid, lipid, and glucose homeostasis. Accordingly, …
[HTML][HTML] Clinical predictors of response to clozapine in patients with treatment resistant schizophrenia
…, S Bhuvaneshwari, B Poonkuzhali… - Psychopharmacology …, 2011 - ncbi.nlm.nih.gov
Objectives Despite clozapine’s superior clinical efficacy in Treatment Resistant Schizophrenia
(TRS), its adverse effects, need for periodic leukocyte monitoring, cost and variable …
(TRS), its adverse effects, need for periodic leukocyte monitoring, cost and variable …
Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with …
AP Rajkumar, B Poonkuzhali, A Kuruvilla… - …, 2012 - Springer
Rationale Pharmacogenetics of schizophrenia has not yet delivered anticipated clinical
dividends. Clinical heterogeneity of schizophrenia contributes to the poor replication of the …
dividends. Clinical heterogeneity of schizophrenia contributes to the poor replication of the …
Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation
B Poonkuzhali, M Chandy, A Srivastava… - Drug metabolism and …, 2001 - ASPET
… Patients were randomly assigned to two groups, A and B, conditioned as follows: regimen
A, 16 mg/kg busulfan + 200 mg/kg cyclophosphamide + antithymocyte globulin; regimen B, …
A, 16 mg/kg busulfan + 200 mg/kg cyclophosphamide + antithymocyte globulin; regimen B, …